prostate cancer
Conditions
Interventions
Carbon-ion beam total dose 51.6 GyE 12 fractions
Sponsors
SAGA HIMAT foundation
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Patients of prostate cancer with pathollogical diagnosis 2) Patients with T1c-3N0M0 tumour accrdiong to UICC(International Union Against Cancer) TMN classification of Malignant tumours 7th edition. 3) Perfomance status of the patient is from zero to two. 4) Life expectancy of the patients is longer than one year. 5) Regarding risk group and hormonal therapy, patients are matched following (a) or (b); (a) low risk patients have never received hormonal therapy, (b) intermediate patients and high risk patients received hormonal therapy longer than four months and shorter than eight months at the first day of the carbon-ion radiotherapy.
Exclusion criteria
Exclusion criteria: 1) Patients have received radiotherapy at the same position where carbon-ion radiotherapy is palanned. 2) Patients have received any kinds of therapies except hormonal therapy. 3) Patients have any other active malignancies. 4) Patients with active and intractable infection at the same position where carbon-ion radiotherapy is palanned. 5) Patients with evidence of elevation of PSA after starting of hormonal therapy and before starting of carbon-ion radiotherapy.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| overall survival rate, cause-specific survival rate, normal tissue reaction, quality of life | — |
Primary
| Measure | Time frame |
|---|---|
| (biochemically or clinically) relapse free survival rate | — |
Countries
Japan
Contacts
Public ContactToyama Shingo
SAGA HIMAT foundation Ion Beam Therapy Center
Outcome results
None listed